Regulatory Peptides as Tumour Markers

Reference

• McGuigan JE. Antibodies to the carboxyl-terminal tetrapeptide of gastrin. Gastoenterology 1967; 53: 697
   PubMed Web of Science ®Google Scholar
• McGuigan J E, Wolfe MM. Secretin injection test in the diagnosis of gastrinoma. Gastroenterology 1980; 79: 1324
   PubMed Web of Science ®Google Scholar
• Rehfeld J. Strukturlikhet ger samband med pankreas- och magtarmcancer? Läkartidningen 1985; 82: 194
   Google Scholar
• Håkansson R, Bengmark S, Brodin E, Ingemarsson Larsson L I, Nilsson G, Sundler F. Substance P-like immunoreactivity in intestinal carcinoid tumours. Substance P, U S von Euler, B Pernow. Raven Press, New York 1977; 55
   Google Scholar
• Norheim I, Theodorsson-Norheim E, Brodin E, öberg K, Lundquist G, Rosell S. Antisera raised against eledoisin and kassinin detect elevated levels of immunoreactive material in plasma and tumour tissues from patients with carcinoid tumours. Regul Pept 1984; 9: 245
   PubMed Web of Science ®Google Scholar
• Theodorsson-Norheim E, Norheim I, öberg K, et al. Neuropeptide K a major tachykinin in plasma and tumour tissues from carcinoid patients. Biochem Biophys Res Commun 1985; 131: 77
   PubMed Web of Science ®Google Scholar
• Martling C R, Theodorsson-Norheim I, Lundberg JM. Bronchoconstriction and hypotensive effects in relation to pharmacokinetics of tachykinins in the guinea-pig. Evidence for extraneuronal cleavage of neuropeptide K to neurokinin A. Naunyn Schmiedebergs Arch. Pharmacol. 1987; 336: 183
   Google Scholar
• Norheim I, öberg K, Theodorsson-Norheim E, et al. Malignant carcinoid tumours; An analysis of 103 patients with regard to tumour localization, hormone production and survival. Ann Surg 1987; 206: 115
   PubMed Web of Science ®Google Scholar
• Feldman J M, O'Dorisio TM. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumours. Am J Med 1986; 81: 41, Suppl 6 B
   PubMed Web of Science ®Google Scholar
• Norheim I, Theodorsson-Norheim E, Brodin E, öberg K. Tachykinins in carcinoid tumours; their use as a tumour marker and possible role in the carcinoid flush. J Clin Endocrinol Metab 1986; 63: 605
   PubMed Web of Science ®Google Scholar
• Adrian T E, Allen JM, Terenghi G, et al. Neuropeptide Y in phaeochromocytomas and ganglioneuroblastomas. Lancet 1983; 2: 540
   PubMedGoogle Scholar
• Allen JA, Yeats J C, Causon R, Brown M J, Bloom SR. Neuropeptide Y and its flanking peptide in human endocrine tumours and plasma. J Clin Endocrinol Metab 1987; 64: 1199
   PubMedGoogle Scholar
• Lundberg J M, Hökfelt T, Hemsén A, Theodorsson-Norheim E, Hamberger B, Goldstein M. Neuropeptide Y-like immunoreactivity in adrenaline cells of adrenal medulla and in tumours and plasma of pheochromocytoma patients. Regul Pept 1986; 13: 169
   PubMedGoogle Scholar
• Gleeson M S, Bloom S, Polak J, Henry K, Dowling R. Endocrine tumour in the kidney affecting small bowel structure, motility, and absorptive function. Gut 1971; 12: 773
   PubMed Web of Science ®Google Scholar
• Skogseid B, öberg K, Benson L, et al. A standardized meal stimulation test of the endocrine pancreas for early detection of pancreatic endocrine tumours in multiple endocrine neoplasia type 1 syndrome: Five years experience. J Clin Endocrinol Metab 1987; 64: 1233
   PubMed Web of Science ®Google Scholar
• öberg K, Lundquist G. Meal-stimulated and atropine-inhibit-ed secretion of pancreatic polypeptide in healthy subjects, members of MEA I families and patients with malignant endocrine tumours of the gastrointestinal tract. Regul Pept 1983; 5: 273
   PubMed Web of Science ®Google Scholar
• öberg K, Theodorsson-Norheim E, Norheim I. Motilin in plasma and tumour tissues from patients with the carcinoid syndrome. Possible involvement in the increased frequency of bowel movements. Scand J Gastroenterol 1987; 22: 1041
   PubMed Web of Science ®Google Scholar
• Theodorsson-Norheim E, öberg K, Rosell S, Boström H. Neurotensinlike immunoreactivity in plasma and tumour tissue from patients with endocrine tumours of the pancreas and gut. Gastroenterology 1983; 85: 881
   PubMed Web of Science ®Google Scholar
• Eriksson B. Recent advances in the diagnosis and management of endocrine pancreatic tumours. Acta Universitatis Upsaliensis. Comprehensive summaries of Uppsala Dissertations from the faculty of medicine 1988; 160
   Google Scholar
• Morris H R, Panico M, Etienne T, Tippins J, Girgis S I, McLntyre I. Isolation and characterization of human calcitonin gene-related peptide. Nature 1984; 308: 746
   PubMed Web of Science ®Google Scholar
• Schifter S, Williams E D, Craig RK Hansen HH. Calcitonin gene-related peptide and calcitonin in medullary thyroid carcinoma. Clin Endocrinol 1986; 25: 703
   PubMed Web of Science ®Google Scholar
• Mason RT, Shulkes A, Zajac JD, Fletcher AE, Hardy K J, Martin TJ. Basal and stimulated release of calcitonin gene-related peptide (CGRP) in patients with medullary thyroid carcinoma. Clin Endocrinol 1986; 25: 675
   PubMedGoogle Scholar
• Stage J G, Stadil F, Rehfeld JF. Secretin and the Zollinger-Ellison syndrome: reliability of secretion tests and pathogenetic role of secretin. Scand J Gastroenterol 1978; 13: 501
   PubMedGoogle Scholar
• Nobin A, Karp W, Lunderquist A, Rosengren E, Sandén Sundler F. Localization of carcinoids and pheochromocytomas with vein catheterization and amine determination. Brain Res Bull 1982; 9: 781
   PubMedGoogle Scholar
• Theodorsson-Norheim E, Hemsén A, Brodin E, Lundberg JM. Sample handling techniques when analyzing regulatory peptides. Life Sci 1987; 41: 845
   PubMed Web of Science ®Google Scholar
• Galen R S, Gambino SR. Beyond normality: The predictive value and efficiency of medical diagnoses. John Wiley & Sons, New York 1975
   Google Scholar